Clinimetric Assessment in Parkinson's Disease

Clinimetric assessment in Parkinson’s disease encompasses the systematic evaluation of clinical measurement instruments to ensure they accurately and reliably capture the multi-faceted manifestations of the disorder. Key properties include validity (the extent to which an instrument measures what it purports to measure), reliability (the consistency of results over time or between raters) and responsiveness (the ability to detect meaningful change). Traditional clinician-reported scales such as the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) remain the cornerstone for quantifying motor and non-motor features, yet they face psychometric limitations in very early or subtle disease stages. In response, stakeholder-driven initiatives have accelerated the development of patient-centred and observer-reported outcome measures, alongside the exploration of digital health technologies (DHTs) to supplement in-clinic assessments with real-world, continuous data. Harmonising clinical, patient and digital modalities and integrating biological staging frameworks are emerging as priorities to improve sensitivity to disease progression and therapeutic effects. This evolution supports both individualised patient management and the design of more efficient clinical trials aimed at disease modification.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Clinimetric Assessment in Parkinson's Disease publication trend

The graph below shows the total number of articles in clinimetric assessment in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Clinimetric Assessment: systematic evaluation of measurement properties of clinical instruments, including validity, reliability and responsiveness.

Clinical Outcome Assessment (COA): instrument capturing how a patient feels, functions or survives, comprising patient-reported, observer-reported, clinician-reported and performance-outcome measures.

Patient-Reported Outcome (PRO): direct report from the patient about their health status without interpretation by clinicians or others.

Observer-Reported Outcome (ObsRO): assessment provided by someone other than the patient or professional, reflecting observable behaviours or events.

MDS-UPDRS: standardised rating scale developed by the Movement Disorder Society to quantify motor and non-motor manifestations of Parkinson’s disease.

Digital Health Technology (DHT): devices and applications, such as wearable sensors or mobile apps, used to capture health data outside traditional clinical settings.

References

1. Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances. npj Parkinson's Disease (2024).
2. Embedding Patient Input in Outcome Measures for Long‐Term Disease‐Modifying Parkinson Disease Trials. Movement Disorders (2023).
3. Acceptability of digital health technologies in early Parkinson's disease: lessons from WATCH-PD. Frontiers in Digital Health (2024).
4. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort. Journal of Neurology (2019).